NYSE MKT
ATNM

Actinium Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Actinium Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$6.95
Today's High:
$7.66
Open Price:
$7.32
52W Low:
$4.67
52W High:
$15.12
Prev. Close:
$7.36
Volume:
316448

Company Statistics

Market Cap.:
$222.37 million
Book Value:
2.223
Revenue TTM:
$90000
Operating Margin TTM:
-45026.67%
Gross Profit TTM:
$1.03 million
Profit Margin:
0%
Return on Assets TTM:
-28.69%
Return on Equity TTM:
-61.76%

Company Profile

Actinium Pharmaceuticals Inc had its IPO on 2012-12-27 under the ticker symbol ATNM.

The company operates in the Healthcare sector and Biotechnology industry. Actinium Pharmaceuticals Inc has a staff strength of 49 employees.

Stock update

Shares of Actinium Pharmaceuticals Inc opened at $7.32 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.95 - $7.66, and closed at $6.98.

This is a -5.16% slip from the previous day's closing price.

A total volume of 316,448 shares were traded at the close of the day’s session.

In the last one week, shares of Actinium Pharmaceuticals Inc have increased by +4.96%.

Actinium Pharmaceuticals Inc's Key Ratios

Actinium Pharmaceuticals Inc has a market cap of $222.37 million, indicating a price to book ratio of 3.8517 and a price to sales ratio of 266.6914.

In the last 12-months Actinium Pharmaceuticals Inc’s revenue was $90000 with a gross profit of $1.03 million and an EBITDA of $-40272000. The EBITDA ratio measures Actinium Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Actinium Pharmaceuticals Inc’s operating margin was -45026.67% while its return on assets stood at -28.69% with a return of equity of -61.76%.

In Q1, Actinium Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Actinium Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
6.8399
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.58 per share while it has a forward price to earnings multiple of 6.8399 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Actinium Pharmaceuticals Inc’s profitability.

Actinium Pharmaceuticals Inc stock is trading at a EV to sales ratio of 156.9242 and a EV to EBITDA ratio of -5.4741. Its price to sales ratio in the trailing 12-months stood at 266.6914.

Actinium Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$102.03 million
Total Liabilities
$7.86 million
Operating Cash Flow
$-76000.00
Capital Expenditure
$76000
Dividend Payout Ratio
0%

Actinium Pharmaceuticals Inc ended 2024 with $102.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $102.03 million while shareholder equity stood at $57.21 million.

Actinium Pharmaceuticals Inc ended 2024 with $35.00 million in deferred long-term liabilities, $7.86 million in other current liabilities, 26000.00 in common stock, $-299802000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $94.52 million and cash and short-term investments were $94.52 million. The company’s total short-term debt was $506,000 while long-term debt stood at $0.

Actinium Pharmaceuticals Inc’s total current assets stands at $98.55 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.

In 2024, Actinium Pharmaceuticals Inc's operating cash flow was $-76000.00 while its capital expenditure stood at $76000.

Comparatively, Actinium Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$6.98
52-Week High
$15.12
52-Week Low
$4.67
Analyst Target Price
$31.8

Actinium Pharmaceuticals Inc stock is currently trading at $6.98 per share. It touched a 52-week high of $15.12 and a 52-week low of $15.12. Analysts tracking the stock have a 12-month average target price of $31.8.

Its 50-day moving average was $6.75 and 200-day moving average was $8.98 The short ratio stood at 7.38 indicating a short percent outstanding of 0%.

Around 225.8% of the company’s stock are held by insiders while 2221.6% are held by institutions.

Frequently Asked Questions About Actinium Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Actinium Pharmaceuticals Inc is ATNM

The IPO of Actinium Pharmaceuticals Inc took place on 2012-12-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Atomera Inc (ATOM)
$6.07
0.05
+0.83%
$393.15
-31.2
-7.35%
$3.53
-0.15
-4.08%
$32.86
0.32
+0.98%
SWAN ENERGY LTD. (SWANENERGY)
$279.05
-22.65
-7.51%
$131.35
-11.85
-8.28%
$1.24
0.02
+1.64%
$9.08
-0.01
-0.11%
$146.25
-7.95
-5.16%
$4.32
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

Address

275 Madison Avenue, New York, NY, United States, 10016